#JPM23: Did the IRA kill that drug?

Phar­ma com­pa­nies were loud and clear ahead of the pas­sage of Medicare price set­ting leg­is­la­tion in the In­fla­tion Re­duc­tion Act: Once passed, drugs that no longer worked in the new math of the leg­is­la­tion would need to be cut.

And with­in weeks of the law be­ing en­act­ed, we be­gan to see that hap­pen, with com­pa­nies like Eli Lil­ly and Al­ny­lam claim­ing ear­ly stage as­sets had to be shut down. Mov­ing for­ward, what’s to stop any com­pa­ny from claim­ing that every pipeline dele­tion is the re­sult of the IRA? How big will the im­pact re­al­ly be? What else should be ex­pect­ed? And are de­vel­op­ers sim­ply find­ing a con­ve­nient vil­lain to blame? Tune in be­low to find out more from the ex­perts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER